Bernstein Calls UnitedHealth Stock (UNH) a Top Pick Ahead of Q2 Earnings

UnitedHealth Group (UNH) stock has fallen 42% year-to-date due to elevated Medicare Advantage costs, a CEO departure, guidance withdrawal, and a DOJ probe. Despite an anticipated 31% YoY Q2 EPS decline to $4.88, Bernstein has named UNH a "Top Pick," citing a "very attractive entry point" at 13.5x P/E. The firm expects UNH to benefit from a hardening government MCO market and normalizing utilization, projecting a doubling of EPS from 2025 to 2029 with a 19% CAGR, driven by sector and company-specific margin recovery, with Wall Street maintaining a Moderate Buy rating and a $355.74 price target.

Analysis

UnitedHealth Group (UNH) is navigating a period of significant stress, evidenced by a 42% year-to-date stock decline driven by elevated Medicare Advantage costs, a sudden CEO departure, the withdrawal of full-year guidance, and a Department of Justice probe into its billing practices. The market anticipates near-term pain, with Wall Street forecasting a more than 31% year-over-year drop in Q2 2025 earnings per share to $4.88. However, Bernstein presents a contrarian bullish thesis, labeling UNH a "Top Pick" and framing the sell-off as a "very attractive entry point." This view is predicated on a valuation of 13.5x P/E, which is 50-60% below pre-COVID relative levels, and the expectation of future catalysts including a "hardening" pricing market for government MCOs and normalizing cost utilization. While Bernstein lowered its 2025 EPS estimate by 10% to account for current pressures, it projects a doubling of EPS from 2025 to 2029, representing a 19% CAGR driven by sector-wide and company-specific margin recovery. This recovery is expected to begin in Q3 for Medicaid and Q1 2026 for Medicare Advantage. The broader Wall Street consensus remains a "Moderate Buy," with an average price target of $355.74 suggesting 21.6% upside, largely aligning with the view that current challenges are priced in.

Key Decisions for Investors

• Given the stock's significant pullback and depressed 13.5x P/E multiple, long-term investors may consider the current valuation an attractive entry point, in line with the analyst's contrarian thesis.
• Investors should closely monitor the upcoming Q2 earnings call on July 29 for management commentary on cost utilization trends and any updates on the DOJ investigation, as these are the primary risks clouding the stock.
• The investment case hinges on a future recovery, so it is prudent to watch for signs of a hardening MCO pricing environment and margin normalization, which are the key catalysts for the projected 19% EPS CAGR through 2029.